Understand the source comparison
Best Peptides for Chronic Pain: Research Comparison
BPC-157 Angiogenesis via VEGF upregulation; NO pathway modulation Tendons, ligaments, muscle, gastric mucosa Subcutaneous injection near injury site Twice daily (short half-life ~4 hours) Strongest evidence for vascular-dependent tissue repair; requires consis
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Angiogenesis via VEGF upregulation; NO pathway modulation
- Tendons, ligaments, muscle, gastric mucosa
- Subcutaneous injection near injury site
- Twice daily (short half-life ~4 hours)
- Strongest evidence for vascular-dependent tissue repair; requires consistent dosing due to short half-life
- Thymosin Beta-4 (TB-500)
- Actin polymerization; cellular migration and matrix remodeling
- Muscle, tendon, ligament, cardiac tissue
- Subcutaneous or intramuscular injection
- Once weekly (half-life 7–10 days)
- Best for structural damage requiring cellular scaffolding; convenient dosing schedule
- KPV (Lys-Pro-Val)
- NF-κB inhibition; selective anti-inflammatory without immunosuppression
- GI tract, joints, systemic inflammation
- Oral or subcutaneous
- Once or twice daily
- Unique mechanism for inflammatory pain without broad immune suppression; oral bioavailability is an advantage
- Dihexa
- BDNF/TrkB pathway agonism; neuroplasticity and synaptogenesis
- Central and peripheral nervous system
- Once daily
- Primarily neuroprotective; indirect pain modulation through neural repair rather than inflammation
- Cerebrolysin
- Neurotrophic factor complex (BDNF, NGF, CNTF)
- CNS; peripheral nerve regeneration
- Intramuscular injection
- Daily for 10–20 days, then cycle off
- Evidence for neuropathic pain models; requires professional administration